Aethlon Medical achieves DARPA milestones
Aethlon Medical has completed multiple milestone achievements under a contract with the Defense Advanced Research Projects Agency, including a milestone validation that the Aethlon Hemopurifier is able to capture the Middle East Respiratory Syndrome Coronavirus. The Hemopurifier is a first-in-class medical device designed to rapidly eliminate viral pathogens from the circulatory system of infected individuals. Most people identified as infected with MERS-CoV develop severe acute respiratory illness. The Hemopurifier is currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens. Beyond the MERS-CoV milestone, Aethlon achieved all 29 milestone opportunities that were provided to the company through DARPA's Dialysis-Like Therapeutics program, resulting in earned revenues of $5,935,996 over the 5-year program.